CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
侵袭性 B 细胞淋巴瘤患者的 CAR-T 细胞治疗：治疗开展十年后的当前展望
英文原题：Chimeric antigen receptor T-cell (CAR-T) therapy in patients with aggressive B-cell lymphomas. Current outlook after a decade of treatment.
查看英文原题
Chimeric antigen receptor T-cell (CAR-T) therapy in patients with aggressive B-cell lymphomas. Current outlook after a decade of treatment.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
CAR-T 细胞疗法已经彻底改变了免疫化疗后难治或复发的弥漫性大B细胞淋巴瘤（DLBCL）患者的治疗。该策略包括对患者自身的T淋巴细胞进行基因修饰，以促进对选定肿瘤抗原的识别。目前，西班牙已批准两种抗CD19 CAR-T 药物用于既往接受过两线或以上治疗的DLBCL患者，并且有多项正在进行的临床试验探索更早的治疗线数。临床试验和上市后真实世界数据均有助于更好地界定每种构建体的疗效和安全性特征，识别主要的预后反应因素，并改善该疗法每个步骤的管理。本文对所有这些问题进行了综述。
展开英文摘要原文
Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the management of patients with diffuse large B-cell lymphoma (DLBCL) who are refractory or relapse after immunochemotherapy. This strategy consists in genetically modifying the patient's own T lymphocytes to favor the recognition of selected tumor antigens.
Currently, we have two anti-CD19 CAR-T drugs approved in Spain for patients with DLBCL after two or more prior treatment lines and there are multiple ongoing clinical trials exploring earlier lines of treatment. Both clinical trials and post-marketing real-world data have contributed to better define the efficacy and safety profile of each construct, identifying the main prognostic response factors and improving the management of each step in this therapy. All these aspects are reviewed herein.
论文信息
- 作者
- Catalá E、Iacoboni G、Barba P
- 第一作者单位
- Department of Hematology, University Hospital Vall d'Hebron, Barcelona, España.Spain
- 通讯作者单位
- Department of Hematology, University Hospital Vall d'Hebron, Barcelona, España; Department of Medicine, Universitat Autònoma de Barcelona, Bellaterra, España; Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, España. Electronic address: pbarba@vhio.net.Spain
- 文献类型
- 综述
- 期刊
- Medicina clinica2022 Apr 8
- 原文标识
- PubMed 34872767 · DOI 10.1016/j.medcli.2021.10.005